A similar result was reported for HER2-overexpressing breast and gastric cancers, where hyperactivated STAT3 signaling-mediated trastuzumab resistance occurred via a feedback loop comprising FN/EGF/IL-6 upstream mediators [36]. This evidence concerns the gene STAT3 and gastric cancer.